Keith Crandell - Aug 12, 2021 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role
Director
Signature
/s/ Mark McDonnell as Attorney-in-Fact for Keith Crandell
Stock symbol
TWST
Transactions as of
Aug 12, 2021
Transactions value $
-$4,815,377
Form type
4
Date filed
8/13/2021, 06:35 PM
Previous filing
Aug 9, 2021
Next filing
Oct 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TWST Common Stock Sale -$151K -1.41K -74.39% $106.93 486 Aug 12, 2021 Direct
transaction TWST Common Stock Sale -$4.39M -41K -34.3% $106.98 78.6K Aug 12, 2021 By Keith L. Crandell Trust F6
transaction TWST Common Stock Sale -$275K -2.56K -3.25% $107.56 76K Aug 12, 2021 By Keith L. Crandell Trust F7
transaction TWST Common Stock Other $0 -286K -39.41% $0.00 440K Feb 11, 2021 By Arch Venture Fund VII, L.P. F1, F2, F4, F5
transaction TWST Common Stock Other $0 +14.6K +17.61% $0.00 97.3K Feb 11, 2021 By Keith L. Crandell Trust F1, F5
transaction TWST Common Stock Other $0 -114K -39.4% $0.00 175K Feb 11, 2021 By ARCH Venture Fund VIII Overage, L.P. F1, F3, F4, F5
transaction TWST Common Stock Other $0 +1 +0% $0.00 97.3K Feb 11, 2021 By Keith L. Crandell Trust F1, F5
transaction TWST Common Stock Other $0 -215K -48.79% $0.00 226K May 13, 2021 By ARCH Venture Fund VII, L.P. F1, F2, F4, F5
transaction TWST Common Stock Other $0 +10.9K +11.23% $0.00 108K May 13, 2021 By Keith L. Crandell Trust F1, F5
transaction TWST Common Stock Other $0 -85.2K -48.79% $0.00 89.4K May 13, 2021 By ARCH Venture Fund VIII Overage, L.P. F1, F3, F4, F5
transaction TWST Common Stock Other $0 +1 +0% $0.00 108K May 13, 2021 By Keith L. Crandell Trust F1, F5
transaction TWST Common Stock Other $0 -226K -100% $0.00* 0 May 19, 2021 By ARCH Venture Fund VII, L.P. F1, F2, F4, F5
transaction TWST Common Stock Other $0 +11.5K +10.6% $0.00 120K May 19, 2021 By Keith L. Crandell Trust F1, F5
transaction TWST Common Stock Other $0 -89.4K -100% $0.00* 0 May 19, 2021 By ARCH Venture Fund VIII Overage, L.P. F1, F3, F4, F5
transaction TWST Common Stock Other $0 +1 +0% $0.00 120K May 19, 2021 By Keith L. Crandell Trust F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pro-rata distribution of Common Stock held by a limited partnership to its partners for no consideration.
F2 The shares were directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3 The shares were directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4 Keith Crandell is a managing director of ARCH VII LLC and ARCH VIII LLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F5 Change in form of ownership of shares previously reported as beneficially owned by the reporting person.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.39 to $107.37. The reporting person undertakes to provide to TWST, any security holder of TWST, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.405 to $107.70.